NCI SBIR provides
funding, mentoring & networking assistance
for small businesses with next-generation cancer technologies.
The SBIR & STTR Programs are one of the largest sources of early stage technology financing in the United States. We welcome entrepreneurs and small business leaders to this website to explore grant and contract funding opportunities.
Learn how NCI SBIR & STTR Programs have helped small businesses with funding awards that help advance cancer research.
AntiCancer, the San Diego-based biotechnology company, was awarded Phase I and II SBIR grants and contracts that have led to the commercialization of three cancer research tools: MetaMouse®, AngioMouse®, and OncoBrite®.
Developed LuViva, a non-invasive medical device designed to instantly detect cervical disease in a point-of-care setting with a $2.5 million Bridge Award.
The new Funding Opportunity Announcements (FOA) for 2017 Omnibus Soliciation are now available for both SBIR and STTR! Next receipt date is September 5, 2017. For more information, visit Omnibus Solicitations page.
New FOAs: Development of Highly Innovative Tools and Technology for Analysis of Single Cells (PA-17-147/148) [MORE INFO]